Key statistics
As of last trade MediciNova Inc (RMN:BER) traded at 1.60, -21.57% below its 52-week high of 2.04, set on Nov 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.60 |
---|---|
High | 1.60 |
Low | 1.60 |
Bid | 1.78 |
Offer | 2.04 |
Previous close | 1.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 49.05m |
Free float | 47.58m |
P/E (TTM) | -- |
Market cap | 111.83m USD |
EPS (TTM) | -0.1665 USD |
Data delayed at least 15 minutes, as of Nov 13 2024 07:34 GMT.
More ▼
Announcements
- MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
- MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
- MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
- MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
- MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
- MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
- MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
- MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
More ▼